Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO study of daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma
NL-OMON52783Phase 3Active, not recruiting
- Sponsor
- European Myeloma Network
- Start
- Oct 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Daratumumab + pomalidomide + dexamethasone with Pomalidomide + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Oct 2018; status: active, not recruiting.
02
Drugs
daratumumabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON52783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52783.